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We report here a 66-year-old woman diagnosed with bronchioloalveolar carcinoma of the right lung
cT4N2M0. The patient was from the Philippines, had never smoked, and tested positive for an EGFR
mutation. She received geﬁtinib as neoadjuvant therapy for two months and displayed a partial response.
The tumour was resected by performing a right pneumonectomy. The residual viable tumour accounted
for less than 10%. Adjuvant chemotherapy with carboplatin-taxol was administered for four cycles.
Fifteen months post-surgery, two brain metastases were found. Geﬁtinib was prescribed, and one month
later complete radiological response was assessed. The patient remains asymptomatic and without
visible disease four months later. Controlled randomised trials are needed to clarify the role of these
target therapies in the neoadjuvant setting.
 2013 Elsevier Ltd. Open access under CC BY-NC-ND license.1. Case report
A 66-year-old woman from the Philippines, a never-smoker
consulted for chest pain, dyspnea and weight loss. A CT scan
revealed a condensation that almost entirely occupied the right
lung (Fig. 1). A PET scan revealed uptake throughout the right lung,
with an SUV of 10 and mediastinal lymphadenopathy. Bronchos-
copy revealed partial obstruction of the LM and LIF of the bronchus
intermedius. A transbronchial biopsy indicated that the tumour
was bronchioloalveolar carcinoma. An EGFR mutation test was
positive (exon 21). The patient was diagnosed with bronchio-
loalveolar carcinoma stage IIIB, and geﬁtinib treatment with 250
mg/once per day was prescribed. One month later, the patient was
asymptomatic, and a CT scan revealed a response greater than 50%
(Fig. 2). PET/TAC analysis indicated a response of>80%, with an SUV
of 3 and nomediastinal adenopathy.When a right pneumonectomy
was performed post-treatment, the amount of residual viable
tumour found was less than 10%, and reparative ﬁbrous lesions
were present (Fig. 3). Adjuvant chemotherapy with carboplatin-
taxol was then administered for four cycles. The patient came to
our clinic regularly and did not display disease relapse until 15
months after diagnosis, when she experienced blurred vision andencio).
-NC-ND license.phosphenes in the inferior inner quadrant of the right eye. A brain
MRI scan revealed two lesions that were consistent with metasta-
ses in the left occipital and frontal subcortical regions. Geﬁtinibwas
prescribed, and one month later complete radiological response
was observed. The patient remains asymptomatic and without
visible disease four months later.2. Discussion
In 2004, three research groups identiﬁed somatic mutations in
the tyrosine-kinase domain of EGFR that were associated with high
TKI-response rates.1e3 Eighty-ﬁve percent of all EGFR mutations in
non-small cell lung cancer (NSCLC) include exon 19 deletions and
replacement of leucine 858 by arginine (L858R) in exon 21. These
mutations were found more often in groups of patients who dis-
played speciﬁc clinical characteristics (female, Asian, adenocarci-
nomas, non-smokers).4
Published data from 1179 patients showed that more than 70%
of patients with EGFR mutations responded to treatment with TKIs,
whereas only 10% of patients without mutations responded to this
type of treatment.5 An initial assessment conducted by the Spanish
Lung Cancer Group (SLCG) indicated that patients with EGFR mu-
tations who received second-line treatment with geﬁtinib had a
60e90% response, with survival approaching 13 months, whereas
patients without EGFR mutations had a response rate below 10% as
well as statistically lower survival.6,7
Fig. 1. A condensation that occupied nearly the entire right lung was observed at
diagnosis.
Fig. 3. Panoramic image of the lung parenchyma. After treatment, most lung tissue
was replaced by ﬁbrous cellular sparingly, histiocytes with pigment and some in-
ﬂammatory cells. At the bottom right side, normal parenchyma preserved to compare
similar microscope magniﬁcations.
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TKIs. Various studies have demonstrated that response and survival
after erlotinib and geﬁtinib treatment are signiﬁcantly different in
patients with exon 19 deletions than in those with exon 21 muta-
tions.8e10
The SLCG evaluated the feasibility of large-scale EGFR mutation
screening in NSCLC patients and analysed the association between
EGFR mutations and clinical outcomes following treatment with
erlotinib.11 From April 2005 through November 2008, a total of
2105 patients with NSCLC from 129 institutions were prospectively
screened for EGFR mutations. EGFR mutation assessment was
performed centrally at the Catalan Institute of Oncology. Mutations
in the EGFR gene were detected in 350 of the 2105 patients
screened (16.6%). Mutations were detected more frequently in
women (30%), never-smokers (37.7%) and patients with adenocar-
cinomas (17.3%). However, mutations were also observed in men
(8.2%), former smokers (9.5%) current smokers (5.8%), and patients
with large-cell carcinomas (11.5%).
Erlotinib was administered to 217 patients, 113 of whom
received erlotinib as ﬁrst-line therapy and 104 received erlotinib as
second- or third-line therapy. EGFR exon 19 deletion mutations
were detected in 135 tumours, and the L858R mutation was
detected in 82 tumours. Of the 164 patients in whom EGFR muta-
tions were also assessed in serum, 97 carried mutations: exon 19
deletions were present in 64 patients and L858R mutations were
present in 33 patients. The overall response rate was 70.6%, of
which 12.2% were complete responses. The responses to erlotinib
treatment in patients with exon 19 deletion mutations were better
than those in patients with the L858R mutation (odds ratio, 3.08;
95% CI, 1.63 to 5.81; P ¼ 0.001) and in patients 61e70 years of age
(odds ratio, 2.55; 95% CI, 1.32 to 4.96; p ¼ 0.006). The median PFS
was 14 months. The duration of response was similar for patientsFig. 2. A response of greater than 50% was observed one month after starting Geﬁtinib
treatment.receiving ﬁrst- or second-line therapy. The median overall survival
was 28 months for patients receiving ﬁrst-line therapy and 27
months for those receiving second-line therapy. The median PFS
was 16 months for women and 9 months for men (P ¼ 0.003). The
median overall survival was 29 months for women and 18 months
for men. There were no signiﬁcant differences in PFS on the basis of
performance status (PS), age, ﬁrst-line versus second- or third-line
therapy, or smoking history.
Multivariate analysis revealed associations betweenpoor PFS and
male sex and the presence of the L858Rmutation. In themultivariate
analysis of overall survival, PS 1, male sex, the presence of the L858R
mutation, brain metastases, and the presence of bronchioloalveolar
adenocarcinoma were associated with poor prognosis.
Large-scale screening of patients for EGFR mutations, with
subsequent customisation of erlotinib treatment, was demon-
strated to be feasible and to improve outcomes. Subsequently, two
phase III trials of Asian patients with EGFRmutations demonstrated
that progression-free survival was longer for patients receiving
geﬁtinib treatment than for those receiving chemotherapy.12,13
The EURTAC trialdthe most recently published randomised
phase III trialdwas conducted in patients with metastatic lesions.
Overall, 174 patients with EGFR mutations were enrolled from 42
hospitals in France, Italy, and Spain. They were randomised to
receive either erlotinib- or standard-platinum based chemotherapy
as ﬁrst-line therapy for metastases. Median PFS in the erlotinib
treated group was signiﬁcantly higher than that in the group
receiving standard chemotherapy (9.7 months versus 5.2 months,
HR 0.37; p < 0.0001). Median survival was 18.8 months in the
chemotherapy arm and 22.9 months in the erlotinib arm (HR, 0.80;
P ¼ 0.42). This study was the ﬁrst phase III trial conducted in
Western populations to demonstrate the superiority of oral target
therapy to platinum-based chemotherapy as a ﬁrst-line treatment
for metastases.14
No randomised phase III trials have been conducted in the
neoadjuvant setting with geﬁtinib or erlotinib, but some favourable
data already exist, most of which are in the form of case reports.15e19
In 2009, a phase II study of preoperative geﬁtinib administration
during clinical stage I NSCLC was published.20 Thirty-six patients
received 250 mg/d geﬁtinib treatment for one month prior to sur-
gery. A partial response was observed in four patients (11%), and
disease progression was observed in three patients (9%). The
strongest predictor of response was the presence of an EGFR mu-
tation, which was found in 17% of the patients studied.
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the pathological features associatedwith response toTKIs in NSCLC.
The tumours studied included 7 squamous cell carcinomas, 27
adenocarcinomas, one adenosquamous carcinoma and one large-
cell carcinoma. Six of the adenocarcinomas harboured EGFR mu-
tations. After geﬁtinib treatment, the tumours possessing EGFR
mutations demonstrated lower tumour cellularity and a lower
proliferative index, as well as large areas of ﬁbrosis, compared with
adenocarcinomas and non-adenocarcinomas in individuals who
did not possess mutations. However, there were no signiﬁcant
correlations between the degree of ﬁbrosis or whether the tumours
had undergone the epithelial to mesenchymal transition and
radiological changes in tumour size.21
A phase II study of preoperative erlotinib treatment in patients
from four hospitals in the Netherlands who had early stage NSCLC
was recently reported.22 Sixty patients received 150 mg of erlotinib
once daily for three weeks before surgery. PET scans revealed that
27% of the patients displayed metabolic responses, and CT scans
indicated that 5% responded to treatment when RECIST criteria were
used. Therewas a groupwithin thepatient population (female never-
smokers with nonsquamous carcinomas) inwhom the response rate
was 34%. No unexpected complications occurred in surgery.
An important issue is the gold standard test to evaluate the
response to TKIs in the neoadjuvant setting. As we have described
previously, the radiological response observed in CT scans with
respect to RECIST criteria does not correlate adequately with
pathological response. In an effort to address this discrepancy,
Aukema et al. developed a study to prospectively evaluate the use
of 18F-FDG PET/CT in the early identiﬁcation of response to neo-
adjuvant erlotinib treatment.23 In the study, 23 patients diagnosed
with NSCLC received erlotinib treatment once daily for threeweeks.
A PET/CT scanwas performed before and at oneweek after erlotinib
administration. The metabolic responses were compared with the
pathologic responses. Twenty-six percent of patients had a partial
metabolic response, 70% of patients had stable disease and 1 pa-
tient had progressive disease. The median percentage of necrosis in
the metabolic responder group was 70%, and the median percent-
age of necrosis was 40% in the non-responder group. The results of
this study suggest that PET/CT scans can predict response to erlo-
tinib treatment in patients with NSCLC.
The patient in our report met all the clinical criteria that most
common in patients with EGFR mutations: female sex, Asian
ethnicity, never-smoker status and presence of adenocarcinoma.
Because of the large size of the tumour, neither pulmonary nor
mediastinal radical surgery was possible. We opted to use TKI
therapy because of the presence of an EGFR mutation and the
excellent results TKIs have shown in the treatment of metastases.
We performed an early reevaluation of the patient using both CT
and PET scans. We observed a partial response, both radiologic and
metabolic, that had a good correlation with the pathological ﬁnd-
ings. The PFS was 17 months, with brain symptomatic relapse. The
patient achieved complete radiologic response when geﬁtinib was
introduced again.
Given the important results in the metastatic setting and the
favourable data obtained in some neoadjuvant cases, randomised
phase III trials are needed to clarify the role of EGFR TKIs as neo-
adjuvant therapy for patients with activated EGFRmutations. Other
aspects that remain to be clariﬁed are the role of certain mutations
that are insensitive to TKIs, the resistance factors to TKIs and a gold
standard test that can be used to evaluate patient response to TKIs.
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